Literature DB >> 8519439

Prevention of ethanol-induced sympathetic overactivity and degeneration by dexmedetomidine.

P Jaatinen1, P Riihioja, A Haapalinna, E Heinonen, K Kiianmaa, A Hervonen.   

Abstract

The effects of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on rat sympathetic neurons were studied during a 12-day, heavy ethanol exposure. Adult male Wistar rats were given ethanol or isocaloric sucrose three times a day by intragastric intubation. Both acute (a single dose of 300 micrograms/kg p.o.) and chronic (100 micrograms/kg x 2 P.O. throughout the experiment) effects of dexmedetomidine were tested. The superior cervical ganglia (SCG) of the ethanol-exposed, non-dexmedetomidine-treated rats showed an abnormally high overall level of tyrosine hydroxylase immunoreactivity (TH-IR) and catecholamine histofluorescence. However, a subpopulation of neurons had apparently lost their catecholamine synthetic activity, as they exhibited no TH-IR or catecholamine fluorescence. The ethanol-exposed ganglia also showed structural alterations (e.g., decreased neuronal size and increased occurrence of vacuolated neurons). In the ethanol-exposed, chronically dexmedetomidine-treated group, by contrast, the SCG exhibited TH-IR and catecholamine fluorescence intensities comparable to those seen in the control ganglia. All the structural parameters studied, as well, were at the control level in the chronically dexmedetomidine-treated group. The single dose of dexmedetomidine offered only marginal protection against the ethanol-induced alterations. These results suggest that chronic dexmedetomidine treatment may prevent ethanol-induced overactivity and degeneration of catecholaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8519439     DOI: 10.1016/0741-8329(95)00027-o

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  6 in total

1.  Current approaches to the recognition and treatment of alcohol withdrawal and delirium tremens: "old wine in new bottles" or "new wine in old bottles".

Authors:  Theodore A Stern; Anne F Gross; Thomas W Stern; Shamim H Nejad; Jose R Maldonado
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 2.  Dexmedetomidine: applications for the pediatric patient with congenital heart disease.

Authors:  Joseph D Tobias; Punkaj Gupta; Aymen Naguib; Andrew R Yates
Journal:  Pediatr Cardiol       Date:  2011-09-10       Impact factor: 1.655

3.  Gastroprotective effect of lupeol on ethanol-induced gastric damage and the underlying mechanism.

Authors:  Silvéria Regina de S Lira; Vietla Satyanarayana Rao; Ana Carla S Carvalho; Marjorie M Guedes; Talita C de Morais; Antonia L de Souza; Maria Teresa S Trevisan; Alana F Lima; Mariana H Chaves; Flávia A Santos
Journal:  Inflammopharmacology       Date:  2009-07-16       Impact factor: 4.473

Review 4.  Dexmedetomidine for the treatment of alcohol withdrawal syndrome: rationale and current status of research.

Authors:  Andrew J Muzyk; Suzanne Kerns; Scott Brudney; Jane P Gagliardi
Journal:  CNS Drugs       Date:  2013-11       Impact factor: 5.749

5.  Dexmedetomidine as adjunct treatment for severe alcohol withdrawal in the ICU.

Authors:  Samuel G Rayner; Craig R Weinert; Helen Peng; Stacy Jepsen; Alain F Broccard
Journal:  Ann Intensive Care       Date:  2012-05-23       Impact factor: 6.925

6.  Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal.

Authors:  Riley J Lizotte; John A Kappes; Billie J Bartel; Katie M Hayes; Veronica L Lesselyoung
Journal:  Clin Pharmacol       Date:  2014-10-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.